InvestoGain

Investogain Pty Limited
AFS Licence No. 334036

All correspondence to:
admin@delisted.com.au
or by mail to:
PO Box 400
Crows Nest NSW 1585

26 April 2025

Name:

PSIRON LIMITED (PSX)
(This company subsequently changed its name to VIRALYTICS LIMITED. You should refer to that name for Status.)

Date of Listing:

15 October 1986

Subsequent Names:

Company Name	Start Date	End Date
VIRALYTICS LIMITED	28/12/2006

Former Names:

Stock Exchange Status: (updated daily)

This company subsequently changed its name to VIRALYTICS LIMITED. You should refer to that name for Stock Exchange Status.

Legal Status: (updated monthly)

This company subsequently changed its name to VIRALYTICS LIMITED. You should refer to that name for Legal Status.

Capital Gains Tax (CGT) Status: (updated at least quarterly)

This company subsequently changed its name and is now VIRALYTICS LIMITED. You should refer to that name for Capital Gains Tax Status.

Updates, corrections, disagreements please email to admin@delisted.com.au

Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.

Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.

Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.

PSIRON LIMITED(PSX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

	FROM	TO
PSIRON LIMITED	17/08/2000	28/12/2006
MEDICAL INNOVATIONS LIMITED		17/08/2000

Shareholder links

Our website ranking of PSX:

(5 out of 5)

COMPANY WEBSITE:

PSX website

PSX email

PSX investorRelations

PSX announcements

PSX annualreports

REGISTRY:

Level 21, 10 Eagle Street Brisbane QLD 4000

Tel : +61 7 3320 2200 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

Address: Level 1 , 82 Waterloo Road , NORTH RYDE , NSW, AUSTRALIA, 2113
Tel: (02) 9889 1200 Fax: (02) 9889 1288

Date first listed: 15/10/1986
Company Secretary:
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Biotechnology company with a focus on virotherapy treatment for a range of cancers, including melanoma, breast and prostate

News & Events

Expand this box to read and print

name changed to Viralytics Limited	28/12/2006
shares reinstated to quotation	31/08/2006
CBio advises of the sale of its investment in BresaGen at a substantial profit and the placing of shares at $6 per share - Psiron owns 1.2 million shares in CBio Limited (cost price $1.00 per share) - this represents 4.7% of the share capital of the company	14/08/2006
company clarifiies the cash flow numbers set out in the June Quarter Appendix 4c: "Staff costs (item 1.2a) for the quarter are shown as $142,000. Payments to directors and director related entities (item 1.24) are also shown as $142,000. Both of these numbers are correct, however should not be interpreted as being one and the same. The fact that the two figures are identical is purely coincidental. Simply, the composition of each of the numbers is different."	09/08/2006
company releases a copy of a presentation and updates on studies and trials	22/06/2006
company provides a general update covering matters in the notes below and advising that it intends to apply for requotation of its shares upon completion of the public offer	09/06/2006
company announces the formal completion of its "first in man" Phase I trial in Malignant Melanoma	05/06/2006
issues a prospectus and applies for the quotation of an additional 44m ordinary shares - via the prospectus the company seeks to raise approximately $6.6m via a non-renounceable rights issue ("Issue") of approximately 44,069,335 New Shares at a price of $0.15 each on the basis of one New Share for every four ordinary Shares held	31/05/2006
Analytica Limited (ALT) has today announced the formation of a joint venture company in Hong Kong with Zhejiang Lingyang Medical Apparatus Company of Linhai China and J & J Stamina company of Taiwan - the joint venture company is expected shortly to sign a license agreement with Analytica Ltd to manufacture and distribute Analytica new constant flow auto burette and Analytica's retractable needle and syringe technologies - Psiron owns 26.7% of the share capital of Analytica Ltd	16/05/2006
CBio Limited announces the completion of the first Phase 2a trial in Rheumatoid Arthritis in 23 patients - CBio is also concluding studies in both Phase II clinical trials in multiple sclerosis and psoriasis (Psiron owns 1.2 million shares in CBio Limited, 5% of the share capital of the company)	09/05/2006
company advises it is working towards completing a private placement of up to 23.0 million new ordinary shares at 15 cents per share to raise up to $3.45 million - as of today's date, it has completed the placement of 12.0 million shares ($1.8 million) - based on commitments received, it is expected that additional shares will be placed shortly	04/05/2006
quarterly cash flow report to 31 March 2006 shows a deficit at operating level of $1619k	01/05/2006
company appoints AXIS Financial Group as financial advisers	19/04/2006
the company has today been advised by DFS Equities that its current funding proposal has lapsed - the company is currently reviewing alternative funding proposals and is confident that a long term funding option for the company will be announced in the near future	11/04/2006
shares suspended from quotation pending release of an announcement regarding the company's long term funding	10/04/2006
name changed from Medical Innovations Limited	17/08/2000

name changed to Viralytics Limited	28/12/2006
shares reinstated to quotation	31/08/2006
CBio advises of the sale of its investment in BresaGen at a substantial profit and the placing of shares at $6 per share - Psiron owns 1.2 million shares in CBio Limited (cost price $1.00 per share) - this represents 4.7% of the share capital of the company	14/08/2006
company clarifiies the cash flow numbers set out in the June Quarter Appendix 4c: "Staff costs (item 1.2a) for the quarter are shown as $142,000. Payments to directors and director related entities (item 1.24) are also shown as $142,000. Both of these numbers are correct, however should not be interpreted as being one and the same. The fact that the two figures are identical is purely coincidental. Simply, the composition of each of the numbers is different."	09/08/2006
company releases a copy of a presentation and updates on studies and trials	22/06/2006
company provides a general update covering matters in the notes below and advising that it intends to apply for requotation of its shares upon completion of the public offer	09/06/2006
company announces the formal completion of its "first in man" Phase I trial in Malignant Melanoma	05/06/2006
issues a prospectus and applies for the quotation of an additional 44m ordinary shares - via the prospectus the company seeks to raise approximately $6.6m via a non-renounceable rights issue ("Issue") of approximately 44,069,335 New Shares at a price of $0.15 each on the basis of one New Share for every four ordinary Shares held	31/05/2006
Analytica Limited (ALT) has today announced the formation of a joint venture company in Hong Kong with Zhejiang Lingyang Medical Apparatus Company of Linhai China and J & J Stamina company of Taiwan - the joint venture company is expected shortly to sign a license agreement with Analytica Ltd to manufacture and distribute Analytica new constant flow auto burette and Analytica's retractable needle and syringe technologies - Psiron owns 26.7% of the share capital of Analytica Ltd	16/05/2006
CBio Limited announces the completion of the first Phase 2a trial in Rheumatoid Arthritis in 23 patients - CBio is also concluding studies in both Phase II clinical trials in multiple sclerosis and psoriasis (Psiron owns 1.2 million shares in CBio Limited, 5% of the share capital of the company)	09/05/2006
company advises it is working towards completing a private placement of up to 23.0 million new ordinary shares at 15 cents per share to raise up to $3.45 million - as of today's date, it has completed the placement of 12.0 million shares ($1.8 million) - based on commitments received, it is expected that additional shares will be placed shortly	04/05/2006
quarterly cash flow report to 31 March 2006 shows a deficit at operating level of $1619k	01/05/2006
company appoints AXIS Financial Group as financial advisers	19/04/2006
the company has today been advised by DFS Equities that its current funding proposal has lapsed - the company is currently reviewing alternative funding proposals and is confident that a long term funding option for the company will be announced in the near future	11/04/2006
shares suspended from quotation pending release of an announcement regarding the company's long term funding	10/04/2006
name changed from Medical Innovations Limited	17/08/2000

Your browser may reflect a date of printing in American format.

ASX Announcements (courtesy of ASX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

Company Updates

Post your comments here

Please read our Terms before posting comments.

Click here for free access to this company's:
ASX, Legal & CGT Status

Directors' on-market share transactions (last 5)

Click here for the last 20 transactions all companies

Directors & Executives (current)

NAME	TITLE	DATE OF APPT
Bryan Dulhunty	Executive Chairman, Finance Director	10/04/2006
Dennis Feeney	Director
Darren Shafren	Director

Date of first appointment, title may have changed.

Directors & Executives (former)

NAME	TITLE	DATE OF APPOINTMENT	DATE OF RESIGNATION

Date of first appointment, title may have changed.